ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)
This research is an open-label extension study for a new treatment called ML-004, designed for people aged 12 to 46 with autism spectrum disorder. 'Open-label' means both you and your doctor will know you are taking the study medication. It's for people who have already taken part in a previous ML-004 study (ML-004-002). The main goal is to understand more about the safety of ML-004 when taken over a longer period. Around 120 young people and adults are expected to take part across different centres. This study is testing ML-004 in both immediate-release (IR) and extended-release (ER) tablet forms.
نظرة سريعة
ما هو موضوع هذه الدراسة؟
This study is called ML-004 and it's looking into a new medication for people with autism spectrum disorder (ASD). It's designed for individuals aged between 12 and 46 years old. This particular trial is a follow-up, called an 'open-label extension study'. This means it's for people who have already completed an earlier study involving ML-004, and everyone involved – the participants and the doctors – will know that the study medication is being given. The main reason for this study is to gather more information about how safe ML-004 is when it's used for a longer time.
Autism spectrum disorder affects how people communicate and interact with others, and how they experience the world around them. While there are approaches to support individuals with autism, this study is exploring a new potential medication. It's important to understand that this study is not primarily looking at how well the drug works, but rather its safety profile.
By carefully monitoring people taking ML-004 over time, researchers hope to build a more complete picture of any potential side effects or safety concerns. This information is a crucial step in the process of developing new treatments and ensuring they are as safe as possible for patients.
النقاط الرئيسية
- This study is a follow-up for people who have already taken ML-004 in a previous trial.
- The main focus is to check the safety of ML-004 for young people and adults with autism.
- Participants will know they are taking the study medication.
- It's for individuals aged 12 to 46 who meet specific health requirements.
- Regular health checks will be part of taking part.
- يمكنك التوقف عن المشاركة في أي وقت دون التأثير على رعايتك العادية.
من قد يكون مؤهلاً؟
To be considered for this study, you must have already finished the previous ML-004-002 study within the last 90 days. You need to be between 12 and 46 years old when the study starts, and have a clear diagnosis of autism spectrum disorder. It's important that you have someone who can reliably report on your symptoms, such as a family member or carer.
You also need to be able to swallow the study tablets. Your body mass index (BMI) should be 18 or above. If you are taking any other medications for your mental health or any other treatments, they need to have been stable for at least four weeks before you join the study.
There are some reasons why you might not be able to join. These include having certain conditions like Rett syndrome or childhood disintegrative disorder, or if you've had seizures that aren't well controlled, especially in the last six months. The study also cannot include individuals who are at a significant risk of suicidal behaviour, have uncontrolled high blood pressure, or if you are pregnant or breastfeeding. These checks are in place to make sure the study is as safe as possible for everyone involved.
هل يمكن أن تناسبك هذه الدراسة؟
أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.
- I have already finished the ML-004-002 study in the last 3 months.
- I am between 12 and 46 years old.
- I have a diagnosis of Autism Spectrum Disorder.
- I have a trusted person who can help report on my symptoms.
- I can swallow tablets whole.
- I haven't had any uncontrolled seizures in the last 6 months.
ماذا يتضمن المشاركة؟
If you decide to take part in this study, you will be given the study medication, ML-004, in tablet form. Both you and the study team will know you are receiving the medication. You'll have regular visits to the study clinic where the research team will check on your health and any effects of the medication. This will involve physical examinations, blood tests, and discussions about how you're feeling and any symptoms you might have. Your care partner will also play a role in reporting on your symptoms. The exact number of visits, tests, and the total duration of your participation will be explained in detail by the study team, but it's an extension of a previous study, so it will involve ongoing assessments.
المخاطر والفوائد المحتملة
المواقع (21)
- Harmonex Neuroscience Researchالرمز البريدي المؤكددوثان، الولايات المتحدة
- Southwest Autism Research and Resource Centerالرمز البريدي المؤكدفينيكس، الولايات المتحدة
- Cortica Healthcareالرمز البريدي المؤكدغلينديل، الولايات المتحدة
- NRC Research Instituteالرمز البريدي المؤكدأورانج، الولايات المتحدة
- Corticaالرمز البريدي المؤكدSan Rafael, United States
- Yale Child Study Centerالرمز البريدي المؤكدنيو هيفن، الولايات المتحدة
- The Children's Research Instituteالرمز البريدي المؤكدواشنطن العاصمة، الولايات المتحدة
- Abba Medical Groupالرمز البريدي المؤكدميامي، الولايات المتحدة
- APG Research, LLCالرمز البريدي المؤكدأورلاندو، الولايات المتحدة
- University of South Florida Psychiatry and Behavioral Neurosciencesالرمز البريدي المؤكدتامبا، الولايات المتحدة
- Neurobehavioral Medicine Groupالرمز البريدي المؤكدBloomfield Hills, United States
- University of Missouri, Thompson Center for Autism & Neurodevelopmentالرمز البريدي المؤكدكولومبيا، الولايات المتحدة
أسئلة شائعة
ما هو الهدف الرئيسي من هذه الدراسة؟
The main purpose is to learn more about the safety of ML-004 when taken over a longer time by people with autism.
من يمكنه المشاركة في هذه الدراسة؟
It's for people aged 12 to 46 with autism who have already completed a previous ML-004 study.
Will I know if I'm taking the study medication?
Yes, this is an 'open-label' study, meaning everyone will know you are receiving the study medication, ML-004.
What kind of medication is ML-004?
ML-004 is a tablet that might be given in an immediate-release or extended-release form.
ماذا لو غيرت رأيي بشأن المشاركة؟
You are free to leave the study at any point, and it won't affect your regular medical care.
كيفية معرفة المزيد
تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.
هل أنت مهتم بالمشاركة؟
نقاش
مناقشة المجتمع
مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.